Jacobio to Start US/China Trials of KRAS Inhibitor in Solid Tumor Cancers
May 03, 2021 at 05:07 AM EDT
Beijing 's Jacobio Pharma announced US approval to start trials of its KRAS G12C inhibitor in patients with advanced solid tumors. The company plans to enroll patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors that have the KRAS G12C mutation. So far, no KRAS G12C inhibitors have been approved globally. China approved a similar IND application in March. Jacobio will start enrolling patients for both trials in the second half of 2021. More details.... Stock Symbol: (HK: 1167) Share this with colleagues: // //